News: H Lundbeck A/S (HLUKF.PK)

HLUKF.PK on OTC Markets Group

21.17USD
25 Aug 2014
Price Change (% chg)

$-0.14 (-0.66%)
Prev Close
$21.31
Open
$21.17
Day's High
$21.17
Day's Low
$21.17
Volume
150
Avg. Vol
350
52-wk High
$31.33
52-wk Low
$20.50

Search Stocks
Select another date:

Fri, Sep 19 2014

BRIEF-Biotie and Lundbeck bring Selincro onto market in France

* Says Biotie today announced that its partner H. Lundbeck A/S (Lundbeck) has brought Selincro onto market in France

BRIEF-Biotie Therapies Oyj: Selincro enters the market in Germany

Aug 29 - Biotie Therapies Oyj : * Biotie: Selincro enters the market in Germany * Says its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on

NORDIC STOCKS - Factors to watch on Aug 7

HELSINKI, Aug 7 - The following stocks may be affected by newspaper reports and other factors on Thursday:

CORRECTED-Lundbeck maintains 2014 outlook after below-forecast Q2 earnings

COPENHAGEN, Aug 7 - Danish pharmaceutical group Lundbeck posted second-quarter operating profit below forecasts on Thursday, but kept its operating profit and sales outlook for the full year.

BRIEF-Otsuka and Lundbeck submit drug application to FDA

COPENHAGEN, July 14 - H. Lundbeck * Otsuka and lundbeck submit new drug application (NDA) to the United States Food and Drug Administration (FDA) for brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression * The NDA is supported by seven completed clinical Phase 2 or 3 studies in proposed indications * Clinical development program included more than 6,500 individuals, including more than 5,300 who received brexpiprazole Sou

NORDIC STOCKS-Factors to watch on July 10

OSLO, July 10 - The following stocks may be affected by newspaper reports and other factors on Thursday:

UK cost agency backs Lundbeck alcohol dependency drug

LONDON - A novel drug to fight alcohol dependency has been endorsed for use on Britain's state health service by the country's cost-effectiveness watchdog NICE in a boost to its Danish maker Lundbeck.

UK cost agency backs Lundbeck alcohol dependency drug

LONDON, July 10 - A novel drug to fight alcohol dependency has been endorsed for use on Britain's state health service by the country's cost-effectiveness watchdog NICE in a boost to its Danish maker Lundbeck.

BRIEF-Lundbeck provides update on the development programme for desmoteplase

STOCKHOLM, June 27 - H Lundbeck A/S : * Lundbeck provides update on the development program for desmoteplase * Says the study did not meet the primary endpoint * Says will now consult with clinical and regulatory experts about the future

BRIEF-Lundbeck completes tender offer of Chelsea Therapeutics

COPENHAGEN, June 23 - H. Lundbeck : * Has successfully completed tender offer for Chelsea Therapeutics * Merger expected to close today, 62.5 percent of outstanding shares tendered and Notices of Guaranteed Delivery delivered for 16.1 percent of outstanding shares * By acquiring Chelsea Therapeutics, Lundbeck gains the rights to Chelsea Therapeutics' recently FDA-approved product, Northera (droxidopa), which is expected to be launched later in 2014 * Says orphan neurology drug Nor

Select another date:
Search Stocks